Skip to main content

Table 4 Multivariate analysis of correlation between angptl3 and HDL components in the study subjects

From: Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients

Controls vs. T2DM Female controls Female T2DM Male controls Male T2DM
Estimate (95 % CI) Estimate (95 % CI) Estimate (95 % CI) Estimate (95 % CI)p
N in category 149 150 149 150
HDL components
 Cholesterol (mg/dL) 2.57 (0.48 to 4.65)* 1.69 (0.13 to 3.25)* 2.07 (0.14 to 4.00)* 4.36 (2.08 to 6.64)ł
 ApoA-I (μg/mL) 1.14 (0.88 to 1.40)§ 1.25 (0.87 to 1.63)§ −0.03 (−0.42, 0.36) 0.38 (−0.02 to 0.78)
 Serum amyloid A(μg/L) −47.07 (−89.60 to −4.53)* −11.7 (−43.15 to 66.57) −14.19 (−53.93 to 25.56) −6.16 (−50.99 to 38.66)
 Triglyceride (log, mg/dL) 1.00 (0.93 to 1.08) 1.00 (0.93 to 1.07) 1.03 (0.97 to 1.09) 1.12 (1.04 to 1.20)*
 Phospholipid (pg/mL) −5.96 (−74.81 to 62.89) −37.24 (−91.14 to 16.66) −54.71 (−127.59 to 18.18) 83.09 (15.18 to 151.00)*
 Sphingosine-1-phosphate (nmol/L) −14.33 (−88.89 to 60.24) −124.3 (−0.64 to 249.30) −28.02 (−106.40 to 50.37) 16.94 (−84.79 to 118.67)
  1. All associations were adjusted for age, body mass index and lipid lowering drugs (Statins and Niacin). Estimates given with 95 % CI express the difference in HDL components associated with 1-SD increase of ANGPTL3
  2. Significance: § p < 0.0001; ł p < 0.01; * p < 0.05